What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do studies economic and clinical studies suggest there is value using these tests in low risk patients?

What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do studies economic and clinical studies suggest there is value using these tests in low risk patients?

What is the rationale for deploying SNP-based NIPT in larger swaths of the population, especially in lower risk populations? Do studies economic and clinical studies suggest there is value using these tests in low risk patients?

CLICK HERE FOR CME CREDIT

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Peter Benn PhD, DS

Peter Benn PhD, DS

Professor
Department of Genetics and Genome Sciences
University of Connecticut Health Center
Farmington, CT